Clinical Prognostic Score to Predict Relapse in VL
ConditionVisceral Leishmaniasis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorInstitute of Tropical Medicine, Belgium
About this trial
This prospective cohort study has the aim to develop a prognostic tool to predict relapse in patients suffering from visceral leishmaniasis (VL) from VL endemic regions in Ethiopia.
Therefore, comprehensive clinical and laboratory characterization of all confirmed VL patients before and during treatment will be performed in order to identify the factors that determine prognosis of the patients. This approach would result in more efficient patient care and would reduce the case fatality and morbidity, and improve follow-up and care for those at risk of VL relapse.
Eligibility criteria
Qualifiers
clinically or parasitologically confirmed VL
Disqualifiers
Age under 12 years
VL patients already on treatment for 3 days or more
Severe critical condition or other circumstances that make the study medically inadvisable
Unlikely to adhere to follow up visits during the study period (e.g. patients who live or work very far away) AND not reachable by phone for follow-up information
Trial design
Treatments tested in this trial
- No intervention
Treatment groups
741 Participants
are divided into 1 treatment groupSponsors and collaborators
Institute of Tropical Medicine, Belgium
Lead sponsor
University of Gondar
Collaborator
Source ClinicalTrials.gov